Long‐term survival and loss in expectancy of life in a population‐based cohort of 7114 patients with diffuse large B‐cell lymphoma

0
0 / 5 (0 votos)

American Journal of Hematology

Fecha de publicación: 17 may 2018

DOI: https://doi.org/10.1002/ajh.25147

Autores: Sara Ekberg, Mats Jerkeman, Per‐Ola Andersson, Gunilla Enblad, Björn E Wahlin, Sverker Hasselblom, Therese M. Andersson, Sandra Eloranta, Karin E. Smedby

Background: Survival has improved among patients with diffuse large B‐cell lymphoma (DLBCL) with the addition of anti‐CD20 antibody therapy. We aimed to quantify trends and remaining loss in expectation of life (LEL) due to DLBCL at a national population‐based level. Patients diagnosed with DLBCL 2000‐2013 (N = 7114) were identified through the Swedish Lymphoma Registry and classified according to the age‐adjusted International Prognostic Index (aaIPI).

Seguir leyendo